Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Nikhil Gupta, Navjot Kanwar, Anchal Arora, Kavin Khatri, Abhinav Kanwal
Rheumatoid arthritis (RA) and osteoporosis are two chronic disorders that are often seen together. RA is an autoimmune disorder that causes pain and inflammation in the joints, while osteoporosis is a disorder in which the bones become weak and fragile. Risk factors for bone loss in RA include disease activity, longer disease duration, erosive disease, autoantibody positivity, and joint damage leading to impaired physical activity. Recent research has shown that there is a complex interplay between immune cells, cytokines, and bone remodeling processes in both RA and osteoporosis...
March 18, 2024: Clinical Rheumatology
#2
JOURNAL ARTICLE
Silvia Piantoni, Francesca Regola, Fabrizio Angeli, Alessia Caproli, Annalisa Trovati, Cesare Tomasi, Giulia Chiarini, Claudia Rossini, Claudia Agabiti Rosei, Carolina De Ciuceis, Franco Franceschini, Maria Lorenza Muiesan, Damiano Rizzoni, Paolo Airò
BACKGROUND: The evaluation of microvascular alterations might provide clinically useful information for patients with an increased cardiovascular (CV) risk, such as those with rheumatoid arthritis (RA), being the small artery remodeling the earliest form of target organ damage in primary CV diseases, such as arterial hypertension. The evaluation of retinal arterioles is a non-invasive technique aimed to identify an early microvascular damage, represented by the increase of the wall-to-lumen ratio (WLR) index...
2024: Frontiers in Medicine
#3
JOURNAL ARTICLE
Annette H M van der Helm-van Mil
No abstract text is available yet for this article.
February 14, 2024: Lancet
#4
JOURNAL ARTICLE
Kenta Shidahara, Takayuki Katsuyama, Kei Hirose, Kazuya Matsumoto, Shoichi Nawachi, Takato Nakadoi, Yosuke Asano, Yu Katayama, Yoshia Miyawaki, Eri Katsuyama, Mariko Takano-Narazaki, Yoshinori Matsumoto, Ken-Ei Sada, Jun Wada
We present a case of microhematuria, proteinuria and hypocomplementemia that developed in a 55-year-old female who was being treated with an infliximab biosimilar (IFX-BS) for rheumatoid arthritis (RA). Renal biopsy showed lupus nephritis (ISN/RPS classification class IV+V). Treatment with the IFX-BS was discontinued, and treatment with prednisolone, hydroxychloroquine and abatacept was started, resulting in clinical remission of lupus nephritis and RA. Although tumor necrosis factor-α (TNF-α) inhibitors are known to induce production of autoantibodies, symptoms are usually limited to skin involvement or arthritis, and renal complications are rare...
October 30, 2023: Modern rheumatology case reports
#5
JOURNAL ARTICLE
Benedetta Terziroli Beretta-Piccoli, Gustav Buescher, George Dalekos, Kalliopi Zachou, Anja Geerts, Nasser Semmo, Mirjam Kolev, Eleonora De Martin, Maciej K Janik, João Madaleno, Milica Lalosevic Stojkovic, Jérôme Dumortier, Thomas Vanwolleghem, Ida Schregel, Silja Steinmann, Florence Lacaille, Marcial Sebode
BACKGROUND AND AIMS: There is little data on the hepatic efficacy and safety of immunomodulatory drugs used in patients with autoimmune hepatitis (AIH), despite their established use in dermatology, rheumatology and inflammatory bowel diseases (IBD). Our aim was to collect real-life data on the experience of expert centres in treating AIH patients with these drugs, considered unconventional for AIH management. METHODS: Online survey among hepatology centres being part of the European Reference Network on Hepatological Diseases (ERN RARE-LIVER)...
September 14, 2023: Journal of Autoimmunity
#6
JOURNAL ARTICLE
Kaleb Michaud, Philip G Conaghan, Sang Hee Park, Karissa Lozenski, Mirko Fillbrunn, Vadim Khaychuk, Elyse Swallow, John Vaile, Henry Lane, Ha Nguyen, Janet Pope
INTRODUCTION: The efficacy of abatacept is enhanced in anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF)-positive versus -negative patients with rheumatoid arthritis (RA). Four early RA abatacept trials were analyzed to understand the differential impact of abatacept among patients with SeroPositive Early and Active RA (SPEAR) compared to non-SPEAR patients. METHODS: Pooled patient-level data from AGREE, AMPLE, AVERT, and AVERT-2 were analyzed...
May 25, 2023: Rheumatology and Therapy
#7
JOURNAL ARTICLE
Paul Emery, Yoshiya Tanaka, Vivian P Bykerk, Thomas W J Huizinga, Gustavo Citera, Clifton O Bingham, Subhashis Banerjee, Benjamin P Soule, Marleen Nys, Sean E Connolly, Karissa L Lozenski, Joe Zhuo, Robert Wong, Kuan-Hsiang Gary Huang, Roy Fleischmann
INTRODUCTION: One target of rheumatoid arthritis (RA) treatment is to achieve early sustained remission; over the long term, patients in sustained remission have less structural joint damage and physical disability. We evaluated Simplified Disease Activity Index (SDAI) remission with abatacept + methotrexate versus abatacept placebo + methotrexate and impact of de-escalation (DE) in anti-citrullinated protein antibody (ACPA)-positive patients with early RA...
March 3, 2023: Rheumatology and Therapy
#8
JOURNAL ARTICLE
Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP.
Leslie R Harrold, Keith Wittstock, Sheila Kelly, Xue Han, Ying Shan, Lin Guo, Page C Moore, Vadim Khaychuk
INTRODUCTION: Currently there is limited data to drive clinical decision making regarding the choice of biologic/targeted synthetic disease-modifying antirheumatic drugs (DMARD); thus, head-to-head comparisons are needed to help guide prescribing. In recent years, significant advancements have helped clarify the mechanistic basis of the clinical associations of autoantibodies in rheumatoid arthritis (RA). This study evaluated the effectiveness of abatacept versus tofacitinib in anti-cyclic citrullinated peptide (CCP+) patients with rheumatoid arthritis (RA)...
June 2023: Rheumatology and Therapy
#9
REVIEW
Jay P Patel, Nithin Kumar Konanur Srinivasa, Akshay Gande, Madatala Anusha, Hassaan Dar, Dheeraj B Baji
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease that can cause cartilage and bone damage as well as a disability. Various cytokines play an essential role in disease formation such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1, IL-6, IL-17, and macrophages; osteoclast is also activated by the cytokines, which cause bone degradation. Early diagnosis is key to optimal therapeutic success, particularly in patients with well-characterized risk factors for poor outcomes such as high disease activity, presence of autoantibodies, and early joint damage...
January 2023: Curēus
#10
JOURNAL ARTICLE
Josef S Smolen, Robert B M Landewé, Sytske Anne Bergstra, Andreas Kerschbaumer, Alexandre Sepriano, Daniel Aletaha, Roberto Caporali, Christopher John Edwards, Kimme L Hyrich, Janet E Pope, Savia de Souza, Tanja A Stamm, Tsutomu Takeuchi, Patrick Verschueren, Kevin L Winthrop, Alejandro Balsa, Joan M Bathon, Maya H Buch, Gerd R Burmester, Frank Buttgereit, Mario Humberto Cardiel, Katerina Chatzidionysiou, Catalin Codreanu, Maurizio Cutolo, Alfons A den Broeder, Khadija El Aoufy, Axel Finckh, João Eurico Fonseca, Jacques-Eric Gottenberg, Espen A Haavardsholm, Annamaria Iagnocco, Kim Lauper, Zhanguo Li, Iain B McInnes, Eduardo F Mysler, Peter Nash, Gyula Poor, Gorica G Ristic, Felice Rivellese, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Nikolay Stoilov, Anja Strangfeld, Annette van der Helm-van Mil, Elsa van Duuren, Theodora P M Vliet Vlieland, René Westhovens, Désirée van der Heijde
OBJECTIVES: To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing the most recent developments in the field. METHODS: An international task force was formed and solicited three systematic literature research activities on safety and efficacy of disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids (GCs). The new evidence was discussed in light of the last update from 2019. A predefined voting process was applied to each overarching principle and recommendation...
January 2023: Annals of the Rheumatic Diseases
#11
JOURNAL ARTICLE
Shahrzad Bakhtiar, Celia Kaffenberger, Emilia Salzmann-Manrique, Sabine Donhauser, Leon Lueck, Neslihan Edeer Karaca, Luis I Gonzalez-Granado, Esra Hazar, Sevgi Keles, Markus G Seidel, Julia Fekadu, Christoph Königs, Ralf Schubert, Peter Bader, Sabine Huenecke
BACKGROUND: Immune dysregulation as a result of an inborn error of immunity (IEI) leads to the complicated symptoms of refractory multi-organ immune dysregulation. B lymphocytes with immune regulatory capacity (Breg) are activated by environmental triggers and act as regulators of the immune response as observed in several autoimmune diseases. OBJECTIVE: We sought to investigate the Breg profile and the CD21low expressing B cells of patients with LRBA deficiency (N = 6) and non-LRBA deficiency IEI (N = 13) with overlapping clinical symptoms of immune dysregulation...
September 13, 2022: Journal of Autoimmunity
#12
REVIEW
Tai-Li Chen, Kai-Hung Chang, Kuei-Ying Su
Inflammatory arthritis has been reported to be associated with the development of osteoporosis. Recent research has investigated the mechanisms of bone metabolism in chronic inflammatory arthritis such as rheumatoid arthritis (RA) and spondyloarthritis (SpA). Progress in both animal and clinical studies has provided a better understanding of the osteoclastogenesis-related pathways regarding the receptor activator of nuclear factor-κB ligand (RANKL), anti-citrullinated protein antibodies (ACPAs), and Wnt signaling and Dickkopf-related protein 1 (Dkk-1)...
April 8, 2022: International Journal of Molecular Sciences
#13
JOURNAL ARTICLE
Aviya Lanis, Rita Volochayev, David E Kleiner, Anusha Vittal, Theo Heller, Lisa G Rider, Susan Shenoi
BACKGROUND: We present two cases of Nodular Regenerative Hyperplasia (NRH) associated with Juvenile Dermatomyositis (JDM). CASE PRESENTATION: Case 1: A nine-year-old Caucasian male with refractory JDM and anti-NXP2 autoantibodies was diagnosed at age two. Over seven years, he developed arthritis, dysphagia, dysphonia, severe calcinosis, and colitis. Complications included recurrent cellulitis, infections, and hepatosplenomegaly. Multiple medications were chronically used, including prednisone, methotrexate, azathioprine, cyclophosphamide, mycophenolate mofetil, rituximab, tacrolimus, etanercept, abatacept, infliximab, and tocilizumab...
April 20, 2022: Pediatric Rheumatology Online Journal
#14
REVIEW
Mitsuhiro Akiyama, Yuko Kaneko
Rheumatoid arthritis is an autoimmune disease that primarily affects the joints. The emergence of highly effective anti-rheumatic drugs such as biologic agents and janus kinase inhibitors has dramatically improved the management of the disease by preventing irreversible joint destruction and disability. This disease can manifest the serious extra-articular involvements including interstitial lung disease, which has the significant impact on the patients' morbidity and mortality. However, treatment strategy specific for rheumatoid arthritis-associated interstitial lung disease (RA-ILD) has not been yet established...
May 2022: Autoimmunity Reviews
#15
JOURNAL ARTICLE
Omar Jabado, Michael A Maldonado, Michael Schiff, Michael E Weinblatt, Roy Fleischmann, William H Robinson, Aiqing He, Vishal Patel, Alex Greenfield, Jasmine Saini, David Galbraith, Sean E Connolly
INTRODUCTION: The biologics abatacept and adalimumab have different mechanisms of action (MoAs). We analyzed data from patients with rheumatoid arthritis treated in AMPLE (NCT00929864) to explore the pharmacodynamic effects of abatacept or adalimumab on anti-citrullinated protein antibodies (ACPAs) and gene expression. METHODS: AMPLE was a phase IIIb, 2-year, randomized, head-to-head trial of abatacept versus adalimumab. Post hoc analyses of baseline anti-cyclic citrullinated peptide-2 (anti-CCP2, an ACPA surrogate) positive (+) status and ACPA fine-specificity profiles over time, as well as transcriptional profiling (peripheral whole blood), were performed...
April 2022: Rheumatology and Therapy
#16
JOURNAL ARTICLE
Tomoaki Ishigami, Toshihiro Nanki, Takuya Sugawara, Kotaro Uchida, Hiroyuki Takeda, Tatsuya Sawasaki, Lin Chen, Hiroshi Doi, Kentaro Arakawa, Sae Saigo, Ryusuke Yoshimi, Masataka Taguri, Kazuo Kimura, Kiyoshi Hibi, Hiromichi Wakui, Kengo Azushima, Kouichi Tamura, On Behalf Of Oracle Arthritis Investigators
To explore the biological and immunological basis of human rheumatoid arthritis and human atherosclerosis, we planned and reported a detailed design and rationale for Orencia Atherosclerosis and Rheumatoid Arthritis Study (ORACLE Arthritis Study) using highly sensitive, high-throughput, human autoantibody measurement methods with cell-free protein synthesis technologies. Our previous study revealed that subjects with atherosclerosis had various autoantibodies in their sera, and the titers of anti-Th2 cytokine antibodies were correlated with the severity of atherosclerosis...
November 15, 2021: Methods and Protocols
#17
RANDOMIZED CONTROLLED TRIAL
William Rigby, Jane H Buckner, S Louis Bridges, Marleen Nys, Sheng Gao, Martin Polinsky, Neelanjana Ray, Vivian Bykerk
BACKGROUND: Certain risk alleles associated with autoantibody-positive rheumatoid arthritis (RA) have been linked to poorer prognoses. In patients with autoantibody-positive RA, abatacept shows differential efficacy to tumor necrosis factor inhibitors. Our aim was to investigate the relationship between clinical response to abatacept and to adalimumab and presence of risk alleles encoding human leukocyte antigen (HLA)-DRB1 shared epitope (SE) in RA. METHODS: In this head-to-head study, biologic-naïve adults with early (≤ 12 months), moderate-to-severe RA and inadequate response to methotrexate (MTX-IR), autoantibody-positive for both anti-cyclic citrullinated peptide 2 and rheumatoid factor, were randomized 1:1 to receive subcutaneous abatacept 125 mg weekly or subcutaneous adalimumab 40 mg every 2 weeks for 24 weeks with stable, weekly oral MTX...
September 18, 2021: Arthritis Research & Therapy
#18
RANDOMIZED CONTROLLED TRIAL
Marit Stockfelt, Anna-Carin Lundell, Merete Lund Hetland, Mikkel Østergaard, Till Uhlig, Marte Schrumpf Heiberg, Espen A Haavardsholm, Michael T Nurmohamed, Jon Lampa, Dan Nordström, Kim Hørslev Petersen, Bjorn Gudbjornsson, Gerdur Gröndal, Jonathan Aldridge, Kerstin Andersson, Kaj Blennow, Henrik Zetterberg, Ronald van Vollenhoven, Anna Rudin
BACKGROUND: The type I interferon (IFN) gene signature is present in a subgroup of patients with early rheumatoid arthritis (RA). Protein levels of IFNα have not been measured in RA and it is unknown whether they associate with clinical characteristics or treatment effect. METHODS: Patients with early untreated RA (n = 347) were randomized to methotrexate combined with prednisone, certolizumab-pegol, abatacept, or tocilizumab. Plasma IFNα protein levels were determined by single molecular array (Simoa) before and 24 weeks after treatment initiation and were related to demographic and clinical factors including clinical disease activity index, disease activity score in 28 joints, swollen and tender joint counts, and patient global assessment...
July 13, 2021: Arthritis Research & Therapy
#19
REVIEW
L Weibel
Paediatric morphoea (localized scleroderma) is an inflammatory sclerosing disorder of the skin and subcutis associated with tissue atrophy. It is thought that the disease develops on the background of genetic predisposition (e.g. mosaicism for the common linear variant) initiated by various trigger factors, and that detected autoantibodies and inflammatory cytokines represent secondary epiphenomena. In contrast to the common belief that morphoea is a benign self-limiting disorder, long-term data indicate that its chronicity, relapsing nature and extracutaneous complications lead to significant morbidity, particularly when the disease starts in early childhood...
April 2021: Clinical and Experimental Dermatology
#20
REVIEW
Jamie L Felton, Holly Conway, Rachel H Bonami
Islet autoantibodies are the primary biomarkers used to predict type 1 diabetes (T1D) disease risk. They signal immune tolerance breach by islet autoantigen-specific B lymphocytes. T-B lymphocyte interactions that lead to expansion of pathogenic T cells underlie T1D development. Promising strategies to broadly prevent this T-B crosstalk include T cell elimination (anti-CD3, teplizumab), B cell elimination (anti-CD20, rituximab), and disruption of T cell costimulation/activation (CTLA-4/Fc fusion, abatacept)...
January 6, 2021: Biomedicines
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
